Definium Therapeutics (DFTX) Change in Cash (2021 - 2026)

Definium Therapeutics (DFTX) has 6 years of Change in Cash data on file, last reported at $4.7 million in Q1 2026.

• On a quarterly basis, Change in Cash rose 102.45% year-over-year to $4.7 million in Q1 2026; TTM through Mar 2026 was $179.7 million, a 206.01% increase from a year earlier, with the FY2025 full-year figure at -$15.9 million, down 109.14% from the prior year.
• Change in Cash for Q1 2026 stood at $4.7 million, down from $237.9 million in the prior quarter.
• Over the last five years, Change in Cash for DFTX reached as high as $237.9 million in Q4 2025 and fell as low as -$190.9 million in Q1 2025.
• Historically, Change in Cash has averaged $7.6 million across 5 years, with a median of -$12.5 million in 2023.
• Across the five-year window, Change in Cash jumped 6386.57% in 2024 and plunged 437.63% in 2025, its largest moves.
• Year by year, Change in Cash stood at -$12.4 million in 2022, then tumbled by 45.39% to -$18.0 million in 2023, then decreased by 19.72% to -$21.5 million in 2024, then surged by 1204.2% to $237.9 million in 2025, then plunged by 98.03% to $4.7 million in 2026.
• Per Business Quant data, the three most recent Change in Cash figures were $4.7 million in Q1 2026, $237.9 million in Q4 2025, and -$13.4 million in Q3 2025.